Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response (ASPR), specifically within the BARDA Division of Contracts Management and Acquisition, has issued solicitation 75A50121R00013 for the acquisition of medical countermeasures to support pandemic influenza and emerging diseases preparedness. This requirement covers the production and maintenance of various biological products, including cGMP influenza vaccine master and working seed lots, research lots, investigational lots, and commercial-scale bulk lots. The scope also includes the provision of clinical or commercial-scale bulk adjuvants, formulation and filling services for various delivery methods, and extensive storage and stability testing for antigens and adjuvants. Additional tasks involve the manufacture of potency reagents, analytical laboratory testing, non-clinical and clinical studies, and activities related to emerging pathogens.
Work will primarily be performed in Washington, DC, under NAICS 325414 for Biological Product (except Diagnostic) Manufacturing and PSC 6505 for Drugs and Biologicals. The contract features an anticipated base period of performance of 36 months from the date of award, with the possibility of two 12-month extensions via options. The minimum guarantee for the duration of the contract, including options, is $50,000.00. While many line items require firm-fixed pricing, others such as shipping, clinical studies, and disposal will be determined through subsequent Requests for Task Order Response (RTOR) issued to contract awardees.
The response deadline for this combined synopsis/solicitation is September 13, 2021. The solicitation includes 13 attachments, such as multiple amendments, an updated Statement of Work, past performance updates, and administrative details regarding a new email account. The point of contact for this requirement is Wendell Conyers. Participating contractors must provide yields for inactivated, live attenuated, or recombinant products and must meet specific clinical evidence requirements for any proposed adjuvants, particularly regarding antigen-sparing benefits for pandemic influenza or emerging pathogens.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.